ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2021
Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.Cancer medicine · 2023Pooled it
- Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis.Frontiers in oncology · 2023Pooled it
- Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.Nature communications · 2025Trial
- Molecular imaging usingAnnals of nuclear medicine · 2025Trial
- Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.Nature medicine · 2022Trial
- Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Image-based PD-L1 scoring and tumor-infiltrating lymphocytes as predictors for the response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Standardizing pCR/MPR Assessment in NSCLC After Neoadjuvant Therapy: Challenges and Perspectives.Cancers · 2026Review
- [Update on the regression grading of non-small cell lung cancer].Pathologie (Heidelberg, Germany) · 2026Review
- Current practice of pathologic response assessment following chemoimmunotherapy for non-small cell lung cancer (NSCLC) in Germany: first real-world data from the multicentre Re-GraDE study.Histopathology · 2025Article
- Issues and missed opportunities in lymph node assessment after neoadjuvant chemotherapy.The Journal of pathology · 2025Review
- Short-term results of salvage surgery after immune and target therapies in non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non-Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy.Thoracic cancer · 2025Article
- Review
- Development and external validation of a prognostic nomogram for event-free survival in resectable non-small cell lung cancer after neoadjuvant chemoimmunotherapy.Frontiers in oncology · 2025Article
- Pathological responses of primary tumor and lymph nodes in non-small cell lung cancer after neoadjuvant chemoimmunotherapy: a retrospective real-world study.Journal of thoracic disease · 2024Article
- Prognostic significance of a pathological response in metastatic lymph nodes of patients with gastric cancer who underwent neoadjuvant chemotherapy followed by surgery.Surgery today · 2024Article
- Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Clinical utility of [European radiology · 2023Article
- Efficacy of neoadjuvant therapy for lung squamous cell carcinoma and lung adenocarcinoma: A retrospective comparative study.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
introductionMajor pathologic response (MPR), defined as residual viable tumor of less than or equal to 10%, currently serves as a surrogate end point for survival for patients with resectable NSCLC after neoadjuvant chemotherapy. However, the significance of pathologic response in lymph nodes harboring metastatic tumors in such patients remains uncertain. Therefore, we studied the effect of neoadjuvant chemotherapy on resected positive lymph nodes and determined if the degree of pathologic response in the lymph nodes alone (LN-MPR) or in combination with that of the primary tumor (PT-MPR) was able to predict the outcome.
methodsA total of 75 patients with NSCLC who underwent neoadjuvant chemotherapy and completed surgical resection were included in this study. Tissue specimens were retrospectively evaluated by two pathologists blinded to the patients' treatments and outcomes. Specimens were reviewed for the degree of pathologic response in the primary tumor and in any involved lymph nodes. The prognostic performance of LN-MPR alone or in combination with PT-MPR with respect to overall survival (OS) was evaluated using the Kaplan-Meier method and Cox regression model.
resultsLN-MPR was significantly predictive of long-term OS after neoadjuvant chemotherapy. A combination of PT-MPR with LN-MPR was significantly associated with outcome and allowed stratification of patients into three prognostic groups (p = 0.001).
conclusionsLN-MPR in isolation is a reliable predictor of OS in patients with NSCLC receiving neoadjuvant chemotherapy. A combination of LN-MPR with PT-MPR seems to correlate well with the outcome and can be used to predict prognosis in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.